Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 9:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 226 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biopsy of Target Tumor Clear all
Recruiting Phase 1Phase 2 Interventional

Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

NCT03516708
View directory record Official record
Conditions
Rectal Cancer
Interventions
Epacadostat, Short-course radiation therapy, CAPOX chemotherapy, FOLFOX chemotherapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
4
States / cities
Orange, California • Boston, Massachusetts • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 8, 2026, 9:07 PM EDT
Terminated Phase 1 Interventional

FBnTP Imaging of Breast Cancer

NCT02204462
View directory record Official record
Conditions
Breast Cancer
Interventions
FBnTP
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
26 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 8, 2026, 9:07 PM EDT
Recruiting No phase listed Observational

Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer

NCT07645391
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
35 Years to 70 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 8, 2026, 9:07 PM EDT
Completed Early Phase 1 Interventional

Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer

NCT04857697
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Probiotic, Therapeutic Conventional Surgery
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 8, 2026, 9:07 PM EDT
Completed Phase 1 Interventional

CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy

NCT03851237
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
64Cu-DOTA-ECLIi, PET/CT
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 8, 2026, 9:07 PM EDT
Recruiting Not applicable Interventional

Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer

NCT06517901
View directory record Official record
Conditions
Prostate Cancer, Diagnosis
Interventions
Software fusion prostate biopsy, Cognitive fusion prostate biopsy
Procedure
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older · Male only
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Burlington, Massachusetts • Albany, New York • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 8, 2026, 9:07 PM EDT
Withdrawn Phase 2 Interventional

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

NCT06730100
View directory record Official record
Conditions
Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, pH Low Insertion Peptide-exatecan Conjugate CBX-12, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
15
States / cities
Irvine, California • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 8, 2026, 9:07 PM EDT
Completed Not applicable Interventional Results available

EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer

NCT04159025
View directory record Official record
Conditions
Non Small Cell Lung Cancer, NSCLC
Interventions
CoreDx Pulmonary Mini-Forceps
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 8, 2026, 9:07 PM EDT
Completed Not applicable Interventional

Real-Time Optical Biopsy in Improving Lung Cancer Diagnosis in Patients Undergoing Lung Biopsy

NCT03376971
View directory record Official record
Conditions
Lesion, Lung Cancer, Diagnoses Disease
Interventions
Biopsy, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 8, 2026, 9:07 PM EDT
Completed Not applicable Interventional

PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy

NCT03635866
View directory record Official record
Conditions
Prostate Cancer
Interventions
Fluciclovine PET/MRI
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 8, 2026, 9:07 PM EDT
Not listed Early Phase 1 Interventional

Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint

NCT01394042
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proxiscan device
Device
Lead sponsor
Radiological Associates of Sacramento Medical Group Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Roseville, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 8, 2026, 9:07 PM EDT
Not yet recruiting Phase 2 Interventional

Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma

NCT07766187
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Histotripsy, Durvalumab, Biopsy
Device · Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 8, 2026, 9:07 PM EDT
Completed Not applicable Interventional

Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer

NCT01411787
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 8, 2026, 9:07 PM EDT
Recruiting Not applicable Interventional

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

NCT04504604
View directory record Official record
Conditions
Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site
Interventions
FoundationOne CDx and FoundationOne Liquid CDx
Diagnostic Test
Lead sponsor
TargetCancer Foundation
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 8, 2026, 9:07 PM EDT
Not listed No phase listed Observational

KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models

NCT05338073
View directory record Official record
Conditions
Cancer, Predictive Cancer Model, Effects of Chemotherapy
Interventions
Known 3Dx Test
Diagnostic Test
Lead sponsor
Known Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Rochester, Minnesota • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 8, 2026, 9:07 PM EDT
Withdrawn Phase 1 Interventional

Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

NCT02619669
View directory record Official record
Conditions
Breast Cancer
Interventions
TAK-228, Letrozole
Drug
Lead sponsor
Gary Schwartz
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 8, 2026, 9:07 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

NCT06400251
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 8, 2026, 9:07 PM EDT
Completed Phase 2 Interventional Results available

Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study

NCT02967458
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
Perflutren Lipid Microsphere Intravenous Suspension
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 8, 2026, 9:07 PM EDT
Recruiting Not applicable Interventional

Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

NCT05530343
View directory record Official record
Conditions
Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophageal Adenocarcinoma
Interventions
Seattle protocol, WATS3D brushings
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
2,298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Gilbert, Arizona • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 8, 2026, 9:07 PM EDT
Recruiting Not applicable Interventional

Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

NCT05610852
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Cancer
Interventions
Transvesical Single Port Robotic Partial Prostatectomy, High-intensity focused ultrasound (HIFU)
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 8, 2026, 9:07 PM EDT
Completed Phase 2 Interventional

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

NCT06849544
View directory record Official record
Conditions
Prostate Cancer Surgery, Prostate Cancer Metastatic Disease
Interventions
0.03mg/kg ZOPOCIANINE given day of surgery, 0.06mg/kg ZOPOCIANINE given day of surgery, 0.03mg/kg ZOPOCIANINE given day prior to surgery, 0.06mg/kg ZOPOCIANINE given days prior to surgery
Drug
Lead sponsor
Clinton Bahler
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 8, 2026, 9:07 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

NCT04917809
View directory record Official record
Conditions
Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation
Interventions
Erdafitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 8, 2026, 9:07 PM EDT
Active, not recruiting Phase 1 Interventional

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

NCT04214392
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
Interventions
Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery), Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 8, 2026, 9:07 PM EDT
Completed No phase listed Observational

Studying Biomarkers in Patients With Pancreatic Cancer

NCT00900003
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
protein analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 8, 2026, 9:07 PM EDT